UCB Pharma Withdraws Its Marketing Authorisation Application For Lacosamide Pain UCB Pharma, Europe

The European Medicines Agency (EMEA) has been formally notified by UCB Pharma S.A. of its decision to withdraw the application for a centralised marketing authorisation for the medicine Lacosamide Pain UCB Pharma (lacosamide) film-coated tablets. Lacosamide Pain UCB Pharma was expected to be used for the treatment of diabetic neuropathic pain in adults.

More: continued here

Filed under: Diabetes on September 30th, 2008